IQV — IQVIA Holdings Inc.

IQVIA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $4.34 billion, up 10.3% year-over-year (8.1% at constant currency).
• Adjusted Diluted EPS: $3.42, a 9.6% increase year-over-year.
• Full Year Revenue: $16.31 billion, up 5.9% reported (4.8% at constant currency).
• Adjusted EBITDA: Q4 at $1.046 billion (5% growth), full year at $3.788 billion (2.8% growth).
• Free Cash Flow: $2.51 billion for the year, representing 99% of adjusted net income.
• Net Bookings: Over $2.7 billion in Q4, with a book-to-bill ratio of 1.18.
• Backlog: Reached a record $32.7 billion, up 5.3% year-over-year.

2. Strategic Updates and Business Highlights

• Acquisitions: Notable acquisitions include a facility in the U.K. for Phase I trials and Federate Technologies for enhanced patient solutions and payer analytics.
• Partnerships: Strategic collaboration with Amazon Web Services (AWS) to accelerate digital transformation in life sciences.
• AI Integration: Continued investment in AI capabilities, with over 150 AI agents deployed across various use cases.
• New Segment Reporting: Transition to two reporting segments: Commercial Solutions and R&D Solutions, aimed at better alignment with market dynamics.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $17.159 billion and $17.359 billion, including a 150 basis point contribution from M&A.
• Adjusted EBITDA Guidance: Projected between $3.975 billion and $4.25 billion.
• Adjusted Diluted EPS Guidance: Expected between $12.55 and $12.85.
• Q1 2026 Guidance: Revenue expected between $4.50 billion and $4.15 billion, with adjusted EBITDA between $920 million and $940 million.

4. Bad News, Challenges, or Points of Concern

• Customer Decision-Making: Slower decision-making from customers due to macroeconomic uncertainties and pressures from interest rates.
• Trial Cancellations: Slightly above normal range of trial cancellations due to specific issues, although overall demand indicators remain positive.
• Margin Pressure: Q4 margins were impacted by high pass-through growth, with expectations for moderation in 2026.

5. Notable Q&A Insights

• AI Disruption Concerns: CEO Ari Bousbib emphasized that AI is an opportunity rather than a threat, highlighting IQVIA's proprietary data and domain expertise as key differentiators.
• Acquisition Impact: Cedar Gate acquisition expected to enhance payer-provider analytics, contributing approximately $125 million in revenue and $33 million in adjusted EBITDA in 2024.
• Market Dynamics: No significant changes in demand dynamics were noted, with a strong pipeline supporting growth, despite concerns about AI potentially reducing the need for certain services.

Overall, IQVIA demonstrated solid financial performance in Q4 2025, with a positive outlook for 2026, while navigating challenges related to customer decision-making and market conditions. The strategic focus on AI and acquisitions positions the company for continued growth in a competitive landscape.